10x Genomics, INC Form 4 insider transactions

10x Genomics President and Chief Scientific Officer, Benjamin J. Hindson, sold 7,826 shares of Class A Common Stock to cover tax withholding obligations.

10x Genomics CEO Serge Saxonov exercised stock options to acquire 50,000 shares of Class A Common Stock at $1.20 per share, increasing his direct beneficial ownership.

10x Genomics' Chief Financial Officer, Adam Taich, sold 11,888 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, sold 8,283 shares of Class A Common Stock to cover tax withholding obligations.

10x Genomics CEO Serge Saxonov sold 13,261 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

10x Genomics CEO Serge Saxonov reported a gift of 900 Class A Common Stock shares and detailed various beneficial ownership holdings.

10x Genomics CEO Serge Saxonov sold 9,348 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

10x Genomics' Chief Financial Officer, Adam Taich, sold 22,315 shares of Class A Common Stock on August 22, 2025, to cover tax withholding obligations related to restricted stock unit vesting.

Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, sold 7,486 shares of Class A Common Stock to cover tax withholding obligations.

10x Genomics, Inc. CEO and Director Serge Saxonov filed a Form 4 detailing a gift of 1,000 Class A Common Stock shares and outlining his direct and indirect beneficial ownership, including recent transfers to family trusts.

10x Genomics, Inc. Director Sarah A. Teichmann reported the acquisition of 15,357 restricted stock units (RSUs) on June 3, 2025, increasing her beneficial ownership to 34,359 shares.

10x Genomics, Inc. Director Shehnaaz Suliman was granted 15,357 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs) on June 3, 2025, as reported in a recent SEC Form 4 filing.

John R. Stuelpnagel, a Director at 10x Genomics, Inc. (TXG), was granted 15,357 Class A Common Stock Restricted Stock Units (RSUs) on June 3, 2025, increasing his direct beneficial ownership to 359,607 shares.

Kimberly J. Popovits, a Director at 10x Genomics, Inc. (TXG), was granted 15,357 restricted stock units (RSUs) on June 3, 2025, increasing her beneficial ownership to 28,616 shares.

Alan Mateo, a Director at 10x Genomics, Inc. (TXG), was granted 15,357 restricted stock units (RSUs) on June 3, 2025, as part of his compensation.

10x Genomics, Inc. Director Sridhar Kosaraju has been granted 15,357 Class A Common Stock Restricted Stock Units (RSUs) as part of his compensation, vesting quarterly from May 21, 2025.

10x Genomics, Inc. CEO and Director Serge Saxonov has filed a Form 4, disclosing the gifting of 3,000 shares of Class A Common Stock on May 29, 2025, reducing his direct beneficial ownership.

Serge Saxonov, CEO and Director of 10x Genomics, Inc., reported the sale of 9,343 shares of Class A Common Stock to satisfy tax withholding obligations related to restricted stock unit vesting.

Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, Inc., sold 7,485 shares of Class A Common Stock to satisfy tax withholding obligations related to restricted stock unit vesting.

Adam Taich, Chief Financial Officer of 10x Genomics, Inc., sold 4,044 shares of Class A Common Stock for tax withholding purposes related to restricted stock unit vesting.

Serge Saxonov, CEO of 10x Genomics, reports the acquisition of 171,428 shares of Class A Common Stock on March 17, 2025, along with details of beneficial ownership through various trusts.

Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, reports the acquisition of restricted stock units representing a contingent right to receive Class A Common Stock.

Adam Taich, CFO of 10x Genomics, reports the acquisition of Class A Common Stock through restricted stock units (RSUs) on October 23, 2024 and March 17, 2025.

Serge Saxonov, CEO of 10x Genomics, reports stock sales and option exercises, including transactions under a previously established 10b5-1 trading plan.

Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, sold shares of Class A Common Stock to cover tax withholding obligations related to vesting restricted stock units.

10x Genomics CEO Serge Saxonov sold 5,092 shares of Class A Common Stock on February 24, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Director Alan Mateo of 10x Genomics, Inc. purchased 40,000 shares of Class A Common Stock at an average price of $11.1393 on February 21, 2025.

10x Genomics CEO Serge Saxonov exercised stock options and acquired 12,000 shares of Class A Common Stock at $1.2 per share on December 23, 2024.

10x Genomics CEO Serge Saxonov sold 6,693 shares of Class A Common Stock to cover tax obligations and received 1,850 shares as a gift.

Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, sold 5,807 shares of Class A Common Stock to cover tax obligations related to vesting restricted stock units.